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Introduction: Microscopic polyangiitis (MPA) is one of the causes of the pulmonary–renal 
syndrome associated with elevated non-specific markers of inflammation and antineu-
trophil cytoplasmic autoantibody (ANCA) positivity in 50–75%. De novo occurrence of 
the disease in patients on chronic hemodialysis (HD) has not been described.
Case presentation: We presented patient who developed MPO-ANCA-associated 
MPA with lung and musculoskeletal involvement after 4 years on regular HD due to bilat-
eral nephrectomy. After excluding the other causes of MPO-ANCA positivity, diagnosis 
was confirmed even without renal biopsy. Patient received standard immunosuppression 
therapy and he is still in remission after 27 months.
Conclusion: The onset of immune-mediated disease could be observed even after 
introduction of renal replacement therapy, which may be a diagnostic problem. Early rec-
ognition and traditional immunosuppressive regiment may provide successful outcome.
Keywords: microscopic polyangiitis, chronic hemodialysis, binephrectomy, Mpo-aNCa, pulmo
INtRoDUCtIoN
Microscopic polyangiitis (MPA) is one of the antineutrophil cytoplasmic autoantibody-associated 
vasculitis (AAV), along with granulomatosis with polyangiitis (GPA; Wegener’s) and eosinophilic 
granulomatosis with polyangiitis (Churg-Strauss). Antineutrophil cytoplasmic autoantibody 
(ANCA) may be specific for myeloperoxidase (MPO-ANCA) or for proteinase 3 (PR3-ANCA) (1).
Microscopic polyangiitis is one of the causes of the pulmonary–renal syndrome, besides 
Goodpasture’s syndrome, systemic lupus erythematosus, and GPA (2). The onset and relapses 
Abbreviations: MPA, microscopic polyangiitis; ANCA, antineutrophil cytoplasmic autoantibody; HD, hemodialysis; RRT, 
renal replacement therapy; MPO, antineutrophil cytoplasmic autoantibody specific for myeloperoxidase; PR3, antineutrophil 
cytoplasmic autoantibody specific for proteinase 3; AAV, antineutrophil cytoplasmic autoantibody-associated vasculitis; GPA, 
granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; SLE, systemic lupus erythematosus; 
ESRD, end-stage renal disease; TCC, transcellular carcinoma; PIP, proximal interphalangeal; MCP, metacarpophalangeal; CRP, 
C reactive protein; pO2, partial pressure of oxygen in arterial blood; pCO2, partial pressure of carbon dioxide in arterial blood; 
O2, oxygen; CT, computed tomography; PSA, prostate-specific antigen; CEA, carcinoembryonic antigen; CA 19-9, cancer 
antigen 19-9; AFP, alpha-fetoprotein; HBsAg, hepatitis B surface antigen; anti-HCV, anti-hepatitis C antibody; anti-HIV, 
anti-human immunodeficiency virus antibody; NSAID, non-steroid and anti-inflammatory drug; FEV1, forced expiratory 
volume in 1 s; FVC, forced volume vital capacity; FEV1/FVC, FEV1/FVC ratio; DLCO, diffusing capacity for carbon monoxide; 
p-ANCA, perinuclear antineutrophil cytoplasmic antibody; c-ANCA, cytoplasmic antineutrophil cytoplasmic antibody.
taBLe 1 | Biochemical and blood count analysis at hospital admission.
analysis Value analysis Value
Glucose 5.1 mmol/L Uric acid 359 μmol/L
Cholesterol 3.79 mmol/L Urea 23.3 mmol/L
HDL cholesterol 0.64 mmol/L Creatinine 735 μmol/L
LDL cholesterol 1.82 mmol/L CK 11 U/L
Triglycerides 2.93 mmol/L Fibrinogen 6.9 g/L
Albumin 31 g/L Fe 2.1 μmol/L
protein 66 g/L UIBC 20.8 μmol/L
Total bilirubin 6.8 μmol/L TIBC 22.9 μmol/L
Direct bilirubin 1.0 μmol/L Transferrin saturation 0.09
AST 12 U/L Potassium 5.3 mmol/L
ALT 11 U/L Sodium 137 mmol/L
ALP 31 U/L Phosphorus 1.38 mmol/L
GGT 16 U/L Bicarbonates 21 mmol/L
LDH 393 U/L CRp 355.6 mg/L
Complete blood 
count
Value Leukocytic  
formula
%
Leukocytes 9.95 × 109 Neutrophils 78.5
Erythrocytes 3.02 × 1012 Lymphocytes 8.0
Hemoglobin 8.8 g/dL Monocytes 2.3
Hematocrit 0.29 Eosinophils 11.0
MCV 94.7 fL Basophils 0.2
Platelets 284 × 109
Bold font indicates the most important findings in this patients’ blood analysis.
FIGURe 1 | Initial chest radiography.
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of systemic diseases in patient with end-stage renal disease are 
not so common (3). In this case report, we present the patient 
who developed MPO-ANCA-associated MPA with lung and 
musculoskeletal involvement after 4 years of regular hemodialysis 
(HD), and this is, as far as we could found, the first case of 
MPA onset in this specific population.
Case RepoRt
A 72-year-old male underwent right nephrectomy in 2006 
and 2 years later total bladder cystectomy due to disseminated 
ureteral transcellular carcinoma. In November 2010, patients’ 
renal function deteriorated, and after diagnosis of complicated 
pyelonephritis, he underwent left-side nephrectomy. Since then 
he was on chronic HD. He also has a history of arterial hyperten-
sion and smoking.
In June 2014, he was hospitalized due to swollen and pain-
ful wrists, proximal interphalangeal and metacarpophalangeal 
joints, and subfebrile temperature. Physical examination 
revealed lowered right basilar respiratory ton and systolic 
precordial murmur. Laboratory findings at admission revealed 
high CRP level and low hemoglobin level, despite erythropoietin 
therapy and iron supplementation (Table  1). Arterial blood 
gases pointed out acute partial respiratory insufficiency (pO2 
7.3 kPa, pCO2 3.4 kPa, O2 saturation 90%). Chest radiography 
and computed tomography (CT) have shown bilateral pleural 
effusion (more pronounced in the right side) with subsequent 
compressive atelectasis and possible consolidation in lower 
right lung. Diagnostic pleural puncture confirmed exudation 
(protein level 33  g/L). Klebsiella–Enterobacter was isolated 
from the sputum culture, and patient is understood to have 
respiratory infection. Echocardiography revealed mild aortic 
stenosis and pericardial effusion (10 mm), without endocardial 
vegetations. Abdominal ultrasound was insignificant, apart 
form the missing kidneys. Other tests were performed in order 
to explain clinical status and high CRP level including bacteriol-
ogy (hemocultures, coprocultures, nasal and pharyngeal swabs), 
tumor markers (prostate-specific antigen, carcinoembryonic 
antigen, CA 19-9, AFP), and markers of viral hepatitis (hepatitis 
B surface antigen, anti-HCV, anti-HIV), and they all were nega-
tive. Esophagogastroduodenoscopy and total colonoscopy were 
done, and results indicated mild erosive gastritis and diverticu-
losis sigmae.
Antibiotic therapy according to sputum antibiogram 
(Meropenem) was started together with non-steroid and anti-
inflammatory drug. After 14 days of antibiotic therapy, joints were 
still swollen and painful, CRP level was still high (139.3 mg/L), 
and chest radiography revealed infiltrations in middle and upper 
zones of the right lung and middle zone of the left lung (Figure 1). 
We performed respiratory function assessment which pointed 
out restrictive pattern of respiratory disorder [spirometry: 
forced expiratory volume in 1 s (FEV1) 55%, FVC 56%, FEV1/
FVC 101%], and lung diffusion capacity (DLCO) was 59% of 
anticipated and pulmonary CT angiography ruled out pulmonary 
thromboembolism. Results of serology analysis confirmed high 
levels of anti-MPO antibodies and perinuclear antineutrophil 
cytoplasmic antibody (p-ANCA) positivity (Table 2).
Since we could not perform kidney biopsy but have strongly 
positive MPO-ANCA, musculoskeletal and lung symptoms, as 
well as ruling out other reasons for ANCA positivity, diagnosis of 
MPA was established (Table 3). Specific induction therapy with 
intravenous cyclophosphamide (six monthly doses of 800  mg) 
and intravenous methylprednisolone (six monthly pulses with 
3  days of 1  g) was prescribed, followed by oral prednisone 
(0.5 mg/kg). After 1 month, there were no joint symptoms, CRP 
level was almost normal (9.8 mg/L), and arterial blood gases were 
recovered, and after 3  months, chest radiography was normal 
FIGURe 2 | Chest radiography after 3 months of treatment.
taBLe 3 | Clinical manifestations of microscopic polyangiitis, overall 
prevalence, and findings in our patient [adapted according to Ref. (2, 4, 5)].
our 
patient
Constitutional manifestations
Fever (55%) X
Malaise, fatigue, flu-like syndrome X
Weight loss (72%) X
other manifestations of microscopic polyangiitis
Rapidly progressive glomerulonephritis (80–100%)
Pulmonary involvement (alveolar hemorrhage, infiltrates, pleural 
effusion, pleuritis, interstitial fibrosis) (25–55%)
X
Cardiovascular (chest pain, symptoms of heart failure, pericarditis)
Gastrointestinal manifestations (abdominal pain, gastrointestinal 
bleeding, colonic ulcerations) (21–58%)
Neurologic manifestation
Peripheral nervous system: mononeuritis multiplex, distal 
symmetrical polyneuropathy (37–72%)
Central nervous system: cerebral hemorrhage, pachymeningitis, 
non-hemorrhagic cerebral infarctions (17–30%)
Musculoskeletal involvement (arthritis, arthralgia, myalgia) X
Skin manifestations (palpable purpura, livedo reticularis, nodules, 
urticaria, and skin ulcers with necrosis) (30–60%)
taBLe 2 | serology analysis.
analysis Value
Serology
ANA (IIF) 1:40
p-Antineutrophil cytoplasmic 
autoantibody (ANCA) (IIF)
1:640
Anti-MPO at (ELISA) 170.7 RU/ml (normal: <20 RU/mL)
Bold font indicates the most important findings in this patients’ blood analysis.
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(Figure 2). After 6 months, control MPO-ANCA was 0.62 RU/
mL and p-ANCA 1:80.
Patient is still in stable remission after 27 months of induc-
tion therapy followed by maintenance therapy (oral azathioprine 
100 mg/day).
DIsCUssIoN
This case report presents the patient who developed MPO-ANCA-
associated MPA with lung and musculoskeletal involvement after 
4 years on regular HD.
Incident MPA patients are predominantly males (1.8:1.0) 
with an average age of onset between 50 and 60 years and with 
predominant increase of non-specific markers of inflammation 
(erythrocyte sedimentation rate and C reactive protein) and 
normochromic, normocytic anemia (4). Our patient was older, 
but he had characteristic laboratory findings. There is no test that 
has high diagnostic specificity for MPA, since ANCA is detected 
in 50–75% of patients. Among them, 90–95% have perinuclear 
staining pattern (p-ANCA) caused by antibodies against myelop-
eroxidase (MPO-ANCA) (2, 4). Therefore, renal biopsy is of a 
great diagnostic value.
In this patient, there were several diagnostic obstacles. 
Kidneys, as the most frequently involved organs, were missing so 
biopsy was not feasible. Also, it is unusual to expect the onset of 
systemic disease in immunocompromised uremic patients who 
also have very rare relapses of previously diagnosed immune-
mediated disease (3). In addition, we had to exclude the other 
reasons of MPO-ANCA positivity: inflammatory bowel diseases, 
rheumatoid arthritis, infections (endocarditis, tuberculosis, and 
amebiasis), drug-induced vasculitis (hydralazine, propylthi-
ouracil), and malignancy (6–13). Also, patients on HD may have 
elevated p-ANCA or c-ANCA if hemodiafiltration is used, but 
our patient was on standard bicarbonate dialysis (14). We also 
had clinical signs which correlated with these serological find-
ings and finally, after 6 months of immunosuppression therapy, 
p-ANCA level was almost normal.
After the diagnosis of MPA was set, in agreement with pul-
monologist and immunologist, traditional and most frequently 
used treatment with monthly intravenous cyclophosphamide and 
methylprednisolone followed by oral prednisone was introduced. 
This regimen is known to lower mortality in AAV (2, 15). Good 
response to therapy justifies our diagnosis and patient is in stable 
remission after 27 months.
CoNCLUDING ReMaRKs
In conclusion, the onset of immune-mediated disease could be 
observed even after introduction of renal replacement therapy, 
which may be a diagnostic problem. Early recognition and 
traditional immunosuppressive regiment may provide successful 
outcome.
The patient has given his written, informed consent to publish 
the information appearing in the article.
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